يعرض 1 - 2 نتائج من 2 نتيجة بحث عن '"Daniel Pink"', وقت الاستعلام: 0.75s تنقيح النتائج
  1. 1
    Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma

    المؤلفون: Alexander Stein, Lisa Paschold, Joseph Tintelnot, Eray Goekkurt, Svenja-Sibylla Henkes, Donjete Simnica, Christoph Schultheiss, Edith Willscher, Marcus Bauer, Claudia Wickenhauser, Peter Thuss-Patience, Sylvie Lorenzen, Thomas Ettrich, Jorge Riera-Knorrenschild, Lutz Jacobasch, Albrecht Kretzschmar, Stefan Kubicka, Salah-Eddin Al-Batran, Anke Reinacher-Schick, Daniel Pink, Marianne Sinn, Udo Lindig, Wolfgang Hiegl, Axel Hinke, Susanna Hegewisch-Becker, Mascha Binder

    المصدر: JAMA Oncology.

    مصطلحات موضوعية: Adult, Aged, 80 and over, Male, Cancer Research, Receptor, ErbB-2, Programmed Cell Death 1 Receptor, Adenocarcinoma, Middle Aged, Trastuzumab, Ipilimumab, Nivolumab, Oncology, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Aged

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea3441b9be1cce2df53c3dc2bbe538fc
    https://doi.org/10.1001/jamaoncol.2022.2228

    أضف إلى المفضلة
  2. 2
    Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib An exploratory analysis of a randomized clinical trial

    المؤلفون: Sebastian Bauer, Annette Reichardt, Jouni Junnila, Harri Sihto, Peter Reichardt, Raija Kallio, Bengt Nilsson, Mikael Eriksson, Marcus Schlemmer, Peter Hohenberger, Silke Cameron, Heikki Joensuu, Salah-Eddin Al-Batran, Aki Vehtari, Daniel Pink, Kirsten Sundby Hall, Joerg T. Hartmann, Eva Wardelmann

    المساهمون: Clinicum, Translational Cancer Biology (TCB) Research Programme, Heikki Joensuu / Principal Investigator, Department of Oncology, Research Programs Unit, HUS Comprehensive Cancer Center

    المصدر: JAMA Oncology. 3(5):602-609

    مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, RESECTION, Population, 3122 Cancers, Medizin, MESYLATE, PDGFRA, medicine.disease_cause, 03 medical and health sciences, Exon, 0302 clinical medicine, POOR-PROGNOSIS, Internal medicine, medicine, education, RECURRENCE, RISK, ta113, education.field_of_study, Mutation, FRENCH SARCOMA GROUP, GiST, business.industry, ORIGIN, Imatinib, medicine.disease, digestive system diseases, 3. Good health, DELETIONS, 030104 developmental biology, Imatinib mesylate, 030220 oncology & carcinogenesis, Cancer research, Sarcoma, business, medicine.drug, GIST

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3d13f0a88c70e9025c6f2a50ea14cbf
    https://doi.org/10.1001/jamaoncol.2016.5751

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء